Search Results

You searched for : anti-PD-1  

Zumutor Biologics Advances Cancer Care with Novel Immunotherapy ZM008: A First-in-Class Anti LLT1 Antibody

As the ZM008-001 clinical trial progresses, the medical community eagerly awaits the results, which could lead the way for a new era in cancer ...
Jun 13

Evaxion Biotech announces Clinical Collaboration to evaluate Keytruda in melanoma patients

Latest news updates...
Oct 26

ImmixBio and BeiGene to evaluate combination of IMX-110 and Tislelizumab in solid tumors

Latest Pharma News Update...
Aug 31

Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106

Latest Pharma Update...
Aug 23

GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448

With this collaboration GSK is uniquely positioned with access to antibodies that synergistically target all three known CD226 checkpoints - TIGIT, CD96 and PVRIG....
Jun 14

Bristol Myers Squibb announces LAG-3-Blocking antibody Relatlimab and Nivolumab fixed-dose Combination

Significantly improves progression-free Survival vs. Opdivo (nivolumab) in patients...
May 22

Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo

The antibody is indicated for patients with previously untreated Metastatic or unresectable melanoma...
Mar 27

BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors

BioInvent and Transgene, today announced they have received regulatory approval in Belgium for a clinical trial application (CTA) for a Phase l/lla study of ...
Dec 21

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA

...
Dec 18

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA

Patients with newly diagnosed esophageal and GEJ cancer face an aggressive disease with a poor prognosis, despite the currently available treatment options...
Dec 17

KEYTRUDA Plus LENVIMA Combination Demonstrated Statistically Significant Improvement in Overall Survival

...
Dec 16

Merck Receives Positive EU CHMP Opinion for KEYTRUDA as First-Line Treatment for Metastatic Microsatellite Instability

...
Dec 11

Dr. Reddy’s E777 ( Denileukin Diftitox) pre clinical data shows tumor growth inhibition

...
Nov 10

KEYTRUDA plus LENVIMA met the trial’s primary endpoint of progression-free survival

LENVIMA plus everolimus were evaluated versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma...
Nov 10

Merck received US FDA approval for Keytruda

FDA approves expanded indication for Merck’s KEYTRUDA (pembrolizumab) in adult patients with relapsed or refractory classical hodgkin lymphoma (cHL) ...
Oct 16

FDA Approves Expanded Indication for Merck’s KEYTRUDA in Adult Patients With classical Hodgkin Lymphoma (cHL)

...
Oct 15

Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1

Positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo® (cemiplimab) in first-line locally advanced or metastatic non-small cell lung ...
Sep 21

Junshi Biosciences receives FDA Breakthrough Therapy Designation for Toripalimab

Major breakthrough for treatment of Nasopharyngeal Carcinomar ...
Sep 11

Merck’s KEYTRUDA Receives Two New Approvals in Japan

Keytruda would be soon launched in Japan for the treatment of cancerous tumors...
Aug 27

Compugen Reports 4th Quarter and Full Year 2019 Result

Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today declared their 4th and full year report....
Feb 21

20 Matching result(s) found!

-Advertisements-



Trending Now

The Value of Risk Communication in Public HealthOctober 08, 2026
What Makes a Reliable Health Screening Programme?October 08, 2026
How Language Access Can Improve Patient Communication in Indian HealthcareOctober 07, 2026
Why Health Literacy Matters in Preventive HealthcareOctober 07, 2026
Improving Follow-Up After Diagnostic Testing: Where Systems Commonly Break DownOctober 07, 2026
Improving Follow-Up After Diagnostic Testing: Where Systems Commonly Break DownOctober 07, 2026
How Community Health Workers Support Preventive Care DeliveryOctober 07, 2026
AI in India's Emergency Departments: Reducing Diagnostic DelaysOctober 06, 2026
AI and Patient Consent in India: Who Is Responsible?October 06, 2026
Wearable Technology in Pregnancy: Benefits and LimitsOctober 06, 2026
Remote Monitoring for High-Risk Pregnancies in IndiaOctober 06, 2026
Fortis Escorts Faridabad Launches ‘Sehat Express’ Mobile Bus for Accessible Doorstep Cancer Screening in association with Faridabad Industries Association Charitable Society and Rotary Club FaridabadOctober 05, 2026
Advanced Thrombectomy Saves 60-Year-Old Woman After Severe Heart Attack at KIMS SaveeraOctober 05, 2026
Constipation, Bloating and Long Sitting Hours: Doctors at RG Hospitals Delhi Warn Urban Professionals Not to Ignore Gut ProblemsOctober 05, 2026
Fermenta – Centre of Excellence for Food Fortification Inaugurated at NIFTEM-T, ThanjavurOctober 05, 2026
Alzheimer’s Dementia: Recognising the Signs, Diagnosing Earlier and Changing the Future of Brain HealthOctober 05, 2026
Man Matters Hairfall Case Study 2026: 7 Lakh+ Consultations Reveal How Hair Loss Changes With AgeOctober 05, 2026
Medication Reconciliation: A System-Level Step for Safer Transitions of CareOctober 05, 2026
The Role of Clinical Pharmacists in Safer Medication UseOctober 05, 2026
Nanavati Max Hospital Hosts Max Cancer Congress 2026, Bringing Together Oncology Experts to Explore the Future of Cancer Care October 01, 2026